Olanzapine and JL13 induce cross-tolerance to the clozapine discriminative stimulus in rats

Behavioural Pharmacology

Volumn 18, Issue 1, 2007, Pages 9-17

  Goudie, Andrew J ^a   Cole, Jon C ^a   Sumnall, Harry R ^b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

Author keywords

Antipsychotic drugs; Clozapine; Cross tolerance; Drug discrimination; JL13; Olanzapine; Rat; Tolerance

Indexed keywords

5 (4 METHYLPIPERAZIN 1 YL) 8 CHLOROPYRIDO[2,3 B][1,5]BENZOXAZEPINE FUMARATE; CLOZAPINE; JL 13; NEUROLEPTIC AGENT; OLANZAPINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DRUG CROSS TOLERANCE; DRUG DETERMINATION; DRUG DISCRIMINATION; DRUG EFFECT; DRUG MECHANISM; DRUG SCREENING; DRUG SENSITIVITY; FEMALE; NONHUMAN; RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; APPETITIVE BEHAVIOR; BENZODIAZEPINES; CLOZAPINE; CONDITIONING, OPERANT; DISCRIMINATION LEARNING; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; FEMALE; GENERALIZATION (PSYCHOLOGY); INJECTIONS, INTRAPERITONEAL; LONG-TERM CARE; OXAZEPINES; PIPERAZINES; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 33846262051     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/FBP.0b013e328014138d     Document Type: Article

References (44)

1. Aravagiri M, Teper Y, Marder S (1999). Pharmacokinetics and tissue distribution of olanzapine in rats. Biopharm Drug Dispos 20:369-377.
2. Bruhwyler J, Liegeois J, Chleide E, Rogister F, Delarge J, Mercier M (1992). Comparative study of typical neuroleptics, clozapine and newly synthesised clozapine analogues: correlations between neurochemistry and behaviour. Behav Pharmacol 3:567-579.
3. Bruhwyler J, Liegeois J, Bergman J, Carey G, Goudie A, Taylor A, et al. (1997). JL13, a pyridobenzoxazepine compound with potential atypical antipsychotic activity: a review of its behavioural properties. Pharmacol Res 36:255-264.
4. Carey G, Bergman J (1997). Discriminative-stimulus properties of clozapine in squirrel monkeys: comparison with conventional and novel antipsychotic drugs. Psychopharmacology 132:261-269.
5. Crissman A, Studders S, Becker H (2004). Tolerance to the discriminative stimulus effects of ethanol following chronic inhalation exposure to ethanol in C57BL/6J mice. Behav Pharmacol 15:569-575.
6. Davies M, Compton-Toth B, Hufeisen S, Meltzer H, Roth B (2005). The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine's actions? Psychopharmacology 178:451-460.
7. 2A antagonist, MDL100907. Neuropharmacology 44:404-415.
8. Doat M, Rabin R, Winter J (2002). The effect of chronic treatment with clozapine and haloperidol on stimulus control by DOM. Int J Neuropsychopharmacol 5:153-158.
9. 2A receptor expression in discrete brain areas. Pharmacol Biochem Behav 81:750-757.
10. Ellenbroek B, Liegeois J (2003). JL13, an atypical antipsychotic: a preclinical review. CNS Drug Rev 9:41-56.
11. Ellenbroek B, Liegeois J, Bruhwyler J, Cools A (2001). Effects of JL13, a pyridobenzoxazepine with potential atypical antipsychotic activity, in animal models for schizophrenia. J Pharmacol Exp Ther 298:386-391.
12. Fasciano J, Steele T, Castagnoli N, Katz J, Ricaurte G (1997). The effect of N-methylation on fenfluramine's neurotoxic and pharmacologic actions. Brain Res 763:182-190.
13. Goudie A, Taylor A (1998). Comparative characterisation of the discriminative stimulus properties of clozapine and other antipsychotics in rats. Psychopharmacology 135:392-400.
14. Goudie A, Smith J, Taylor A, Taylor M, Tricklebank M (1998). Discriminative stimulus properties of the atypical neuroleptic clozapine in rats: tests with subtype selective receptor ligands. Behav Pharmacol 9:699-710.
15. Goudie A, Smith J, Cole J (2004a). Stimulus properties of the 'atypical' antipsychotic zotepine in rats: comparisons with clozapine and quetiapine. Pharmacol Biochem Behav 77:163-173.
16. Goudie A, Smith J, Millan M (2004b). Characterization of the effects of receptor-selective ligands in rats discriminating the novel antipsychotic quetiapine. Psychopharmacology 171:212-222.
17. Goudie A, Cooper G, Cole J, Sumnall H (2006). Cyproheptadine resembles clozapine in vivo following both acute and chronic administration. J Psychopharmacol; doi:10.1177/0269881106067076 [Epub ahead of print].
18. 2A receptor signalling in rat cortex. Neuropsychopharmacology 30:1693-1702.
19. Guiso G, Caccia S (2001). Distribution of the methylpiperazinopyridobenzoxazepine derivative JL13, a potential antipsychotic, in rat brain. J Pharm Pharmacol 53:317-321.
20. Invernizzi R, Garavaglia C, Samanin R (2000). JL13, a pyridobenzoxazepine compound with potential atypical antipsychotic activity, increases extracellular dopamine in the prefrontal cortex, but not in the striatum and the nucleus accumbens of rats. Naunyn Schmiedebergs Arch Pharmacol 361:298-302.
21. Kelley B, Porter J (1997). The role of muscarinic cholinergic receptors in the discriminative stimulus properties of clozapine in rats. Pharmacol Biochem Behav 57:707-719.
22. Leucht S, Busch R, Hamann J, Kissling W, Kane J (2005). Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biol Psychiatry 57:1543-1549.
23. M, Fletcher P, Kapur S (2006). Time course of the antipsychotic effect and the underlying behavioural mechanism. Neuropsychopharmacology; doi: 10:1038/sjnpp.1 [Epub ahead of print].
24. Lieberman J, Stroup T, McEvoy J, Swartz M, Rosenheck R, Perkins D, et al. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New Engl J Med 353:1209-1223.
25. Liegeois J, Rogister F, Bruhwyler J, Damas J, Nguyen T, Inarejos M (1994). Pyridobenzoxazepine and pyridobenzothiazepine derivatives as potential central nervous system agents: synthesis and neurochemical study. J Med Chem 37:519-525.
26. Matza L, Baker T, Revicki D (2005). Efficacy of olanzapine and ziprasidone for the treatment of schizophrenia. CNS Drugs 19:499-515.
27. McEvoy J, Lieberman J, Stroup T, Davis S, Meltzer H, Rosenheck R (2006). Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 163:600-610.
28. 1A agonist properties. IV. A drug discrimination comparison with clozapine. J Pharmacol Exp Ther 289:427-436.
29. Millan M, Brocco M, Rivet J, Audinot V, Newman-Tancredi A, Maiofiss L, et al. (2000). S18327 (1-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperid-1-yl]ethyl] 3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: II. Functional profile and a multiparametric comparison with haloperidol, clozapine, and 11 other antipsychotic agents. J Pharmacol Exp Ther 292:54-66.
30. Moran-Gates T, Massarai C, Graulich A, Liegeois J, Tarazi F (2006). Long-term effects of JL 13, a potential atypical antipsychotic, on rat dopamine and serotonin receptor subtypes. J Neurosci Res 84:675-682.
31. Philibin S, Prus A, Pehrson A, Porter J (2005). Serotonin receptor mechanisms mediate the discriminative stimulus properties of the atypical antipsychotic clozapine in C57BL/6 mice. Psychopharmacology 180:49-56.
32. Porter J, Strong S (1996). Discriminative stimulus control with olanzapine: generalization to the atypical antipsychotic clozapine. Psychopharmacology 128:216-219.
33. Porter J, McCallum S, Varvel S, Vann R (2000). The discriminative stimulus properties of the atypical antipsychotic olanzapine in rats. Psychopharmacology 148:224-233.
34. Porter J, Prus A, Vann R, Varvel S (2005). Discriminative stimulus properties of the atypical antipsychotic clozapine and the typical antipsychotic chlorpromazine in a three-choice drug discrimination procedure in rats. Psychopharmacology 178:67-77.
35. Prus A, Baker L, Meltzer H (2004). Discriminative stimulus properties of 1.25 and 5.0 mg/kg doses of clozapine in rats: examination of the role of dopamine, serotonin, and muscarinic receptor mechanisms. Pharmacol Biochem Behav 77:199-208.
36. Prus A, Philibin S, Pehrson A, Porter J (2005). Generalization to atypical antipsychotic drugs depends on training dose in rats trained to discriminate 1.25 mg/kg clozapine versus 5.0 mg/kg clozapine versus vehicle in a three-choice drug discrimination task. Behav Pharmacol 16:511-520.
37. Prus A, Philibin S, Pehrson A, Porter J (2006). Discriminative stimulus properties of the atypical antipsychotic drug clozapine in rats trained to discriminate 1.25 mg/kg clozapine vs. 5.0 mg/kg clozapine vs. vehicle. Behav Pharmacol 17:185-194.
38. Sebens J, Koch T, Ter Horst G, Korf J (1998). Olanzapine-induced Fos expression in the rat forebrain: cross-tolerance with haloperidol and clozapine. Eur J Pharmacol 353:13-21.
39. (2C) receptor antagonist. Neuropsychopharmacology 30:372-380.
40. Smith J, Goudie A (2002). Discriminative stimulus properties in rats of the novel antipsychotic quetiapine. Exp Clin Psychopharmacol 10:376-384.
41. Tang A, Franklin S, Himes C, Smith M, Tenbrink R (1997). PNU-96415E, a potential antipsychotic agent with clozapine-like pharmacological properties. J Pharmacol Exp Ther 281:440-447.
42. Walker E, Richardson T, Young A (1997). Tolerance and cross-tolerance to morphine-like stimulus effects of mu opioids in rats. Psychopharmacology 133:17-28.
43. Young A (1991). Tolerance to drugs acting as discriminative stimuli. In: Glennon R, Jarbe T, Frankenheim J, editors. Drug discrimination: applications to drug abuse research. NIDA Research Monograph 116, pp. 197-212.
44. Young A, McMullen W, Makhay M, Goushaw P (1996). Behavioral contingencies modulate tolerance to discriminative stimulus effects of morphine. Psychopharmacology 125:220-230.